Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,243 across all filing types
Latest filing 2024-06-21 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Disclosure pursuant to Regulation 30 of the SEBI LODR Regulations 2015 is enclosed.
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It notifies the exchanges about an order received from the Food and Drugs Administration (FDA) regarding the suspension of the company's manufacturing license for a specified period. The document includes details of the order, the nature of the violation, and the company's response. There are no financial statements, earnings data, or detailed management analysis present. The document is a regulatory announcement about a legal/regulatory action affecting the company, not a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-21 English
Credit Rating
Regulatory Filings
2024-06-19 English
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CSD-PoD-1/P/CIR/2023/123 ....
Regulatory Filings
2024-06-19 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under an Employee Stock Options Plan (ESOP). It details the number of shares allotted, the increase in issued share capital, and compliance with SEBI regulations. There are no financial statements, management discussion, or earnings data presented. The document is an announcement of a capital change due to ESOP share allotment, not a full financial report or earnings release. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is 4430 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2024-06-10 English
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on June 10, 2024, has approved the allotment of 1,45,000 equity shares of the face value ....
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under an Employee Stock Options Plan (ESOP). It details the number of shares allotted, the increase in issued share capital, and compliance with SEBI regulations. The content focuses on the allotment of shares and capital changes rather than financial performance, management discussion, or earnings. The document length is 4430 characters, which is relatively short and primarily an announcement of a capital change due to ESOP exercise. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-06-10 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-05-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.